Literature DB >> 21154067

Metacognition and social function in schizophrenia: associations over a period of five months.

Paul H Lysaker1, Molly A Erickson, Benjamin Buck, Kelly D Buck, Kyle Olesek, Megan L A Grant, Giampaolo Salvatore, Raffaele Popolo, Giancarlo Dimaggio.   

Abstract

INTRODUCTION: Deficits in the ability to think about thinking have been widely observed in persons with schizophrenia and linked with concurrent assessments of various forms of function. Less is known though about their links to outcome over time. To address this issue, the current study explores whether Mastery, a domain of metacognition that reflects the ability to use knowledge about one's own mental states and those of others to respond to psychological challenges, is related to the frequency of social contact and persons' capacity for social relatedness.
METHODS: Participants were 72 adults with schizophrenia spectrum disorders enrolled in vocational rehabilitation; these patients completed a baseline assessment as well as a follow-up assessment 5 months later. Mastery was assessed using the Metacognitive Assessment Scale and social functioning by the Quality of Life Scale.
RESULTS: Using structural equation modelling, the proposed model demonstrated acceptable fit even when a range of possible confounding variables were entered as covariates.
CONCLUSIONS: . Results are consistent with the possibility that certain forms of metacognition affect social function among persons with schizophrenia, both concurrently and over time.

Entities:  

Mesh:

Year:  2010        PMID: 21154067     DOI: 10.1080/13546805.2010.530470

Source DB:  PubMed          Journal:  Cogn Neuropsychiatry        ISSN: 1354-6805            Impact factor:   1.871


  9 in total

1.  Metacognition: towards a new approach to quality of life.

Authors:  Julien Blanc; Laurent Boyer; Pierre Le Coz; Pascal Auquier
Journal:  Qual Life Res       Date:  2013-08-29       Impact factor: 4.147

2.  Metacognition, Personal Distress, and Performance-Based Empathy in Schizophrenia.

Authors:  Kelsey A Bonfils; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

3.  Metacognition in Early Phase Psychosis: Toward Understanding Neural Substrates.

Authors:  Jenifer L Vohs; Tom A Hummer; Matthew G Yung; Michael M Francis; Paul H Lysaker; Alan Breier
Journal:  Int J Mol Sci       Date:  2015-06-29       Impact factor: 5.923

4.  Attentional control mediates the relationship between social anhedonia and social impairment.

Authors:  Laura M Tully; Sarah Hope Lincoln; Christine I Hooker
Journal:  Front Psychol       Date:  2014-12-03

5.  A pilot study on feasibility, acceptance and effectiveness of metacognitive-oriented social skills training in schizophrenia.

Authors:  Felix Inchausti; Nancy V García-Poveda; Alejandro Ballesteros-Prados; Eduardo Fonseca-Pedrero; Javier Ortuño-Sierra; Sergio Sánchez-Reales; Javier Prado-Abril; José Antonio Aldaz-Armendáriz; Joe Mole
Journal:  BMC Psychiatry       Date:  2017-06-12       Impact factor: 3.630

6.  Autobiographical memory and mentalizing impairment in personality disorders and schizophrenia: clinical and research implications.

Authors:  Giancarlo Dimaggio; Giampaolo Salvatore; Raffaele Popolo; Paul H Lysaker
Journal:  Front Psychol       Date:  2012-11-26

7.  Quality of life is predictive of relapse in schizophrenia.

Authors:  Laurent Boyer; Aurelie Millier; Emeline Perthame; Samuel Aballea; Pascal Auquier; Mondher Toumi
Journal:  BMC Psychiatry       Date:  2013-01-09       Impact factor: 3.630

8.  Intersubjectivity in schizophrenia: life story analysis of three cases.

Authors:  Leonor Irarrázaval; Dariela Sharim
Journal:  Front Psychol       Date:  2014-02-12

9.  The neural basis of theory of mind and its relationship to social functioning and social anhedonia in individuals with schizophrenia.

Authors:  David Dodell-Feder; Laura M Tully; Sarah Hope Lincoln; Christine I Hooker
Journal:  Neuroimage Clin       Date:  2013-11-27       Impact factor: 4.881

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.